New drug could slow lung decline in transplant patients
NCT ID NCT03283007
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 3 trial tests whether nintedanib, a drug already used for lung scarring, can slow the decline in lung function in lung transplant recipients who develop bronchiolitis obliterans syndrome (BOS), a form of chronic rejection. 58 participants received either nintedanib or a placebo twice daily for 6 months. The study measures changes in breathing tests, exercise ability, and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Nintedanib
- What this could lead to
- If it works, this could provide a treatment to slow lung function decline and improve survival in lung transplant patients with chronic rejection.
- What could go wrong
- This is a small, early-phase trial with only 58 participants. The drug may not slow lung decline or could cause side effects. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRONCHIOLITIS OBLITERANS SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Foch Hospital
Suresnes, 92150, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can lung MRI replace CT scans for detecting a serious Post-Transplant lung condition?
- New inhaled therapy aims to slow lung transplant rejection
- Inhaled drug aims to save transplanted lungs from silent threat
- New xenon MRI could spot lung damage in kids after transplant
- New hope for lung scarring after transplant: belumosudil trial launches
- Can a simple home breathing test catch lung trouble early in transplant patients?